[
  {
    "ts": null,
    "headline": "Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer",
    "summary": "WILMINGTON, Del., December 07, 2024--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC",
    "url": "https://finnhub.io/api/news?id=3566e27e8f84a6de8065cac7f198e7f555b052529cb17e51a8c41011e1082773",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733574600,
      "headline": "Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer",
      "id": 131844053,
      "image": "https://media.zenfs.com/en/business-wire.com/a0d18267add94fec2620d87f96003e13",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., December 07, 2024--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC",
      "url": "https://finnhub.io/api/news?id=3566e27e8f84a6de8065cac7f198e7f555b052529cb17e51a8c41011e1082773"
    }
  }
]